Monthly Archives: October 2018

//October

Signing up to myGPhC

The vast majority of registrants have now successfully signed up to myGPhC. 

Please check our updated troubleshooting tips or before contacting us. These resources should answer your query. We are receiving a high volume of calls into our customer contact centre, so it is likely to be quicker and easier for you to look at the information available online.

By |October 31st, 2018|Lexpos News|Comments Off on Signing up to myGPhC

Signing up to myGPhC

The vast majority of registrants have now successfully signed up to myGPhC. 

Please check our updated troubleshooting tips or before contacting us. These resources should answer your query. We are receiving a high volume of calls into our customer contact centre, so it is likely to be quicker and easier for you to look at the information available online.

By |October 31st, 2018|Lexpos News|Comments Off on Signing up to myGPhC

GPhC statement on supplying valproate safely to women and girls

Valproate is a treatment for epilepsy and bipolar disorder. Children born to women who take valproate during pregnancy are at significant risk of birth defects and persistent developmental disorders. As such, it is vital that women and girls are dispen...

By |October 26th, 2018|Lexpos News|Comments Off on GPhC statement on supplying valproate safely to women and girls

GPhC announces results from the September 2018 registration assessment

We are pleased to announce the names of the 544 pre-registration trainee pharmacists who passed their registration assessment in September.

Follow this link to see the pass list

There were 834 candidates who sat our registration assessment on 27 September 2018, with 544 candidates who passed the assessment; a pass rate of 65.2%

By |October 26th, 2018|Lexpos News|Comments Off on GPhC announces results from the September 2018 registration assessment

GPhC statement on Avastin

The GPhC has issued a statement to give clarity to pharmacy professionals and patients and the public on the supply of the drug Avastin off licence for wet age-related macular degeneration (wet AMD). This follows the dismissal in the High Court of a judicial review brought by two pharmaceutical companies against 12 Clinical Commissioning Groups on 21 September 2018.

The full judgment is available to read on their website.

 

By |October 25th, 2018|Lexpos News|Comments Off on GPhC statement on Avastin